

Mid-Congress-Symposium 3

Oncology & Theranostics + Radiopharmacy + Drug Development Committee / European Society for Medical Oncology (ESMO)

Monday, October 26, 14:00-16:45

Session Title

Clinical Development of Radioligand Therapy

Chairperson

Daniela Oprea-Lager (Amsterdam, Netherlands)

Programme

14:00 - 14:29 Anasthasios Stathis (Bellinzona, Switzerland): Overview of Clinical Development (From Phase 0 to 3)

14:29 - 14:58 Ahmad Awada (Brussels, Belgium): Early Development of New Therapeutic Approaches - A Break with the Past

14:58 - 15:27 Günter Waxenecker (Vienna, Austria): Regulatory Aspects of Radioligand Therapies - Approval Pathways and Non-Clinical Requirements

15:27 - 15:42 Break

15:42 - 16:11 Daniela Oprea-Lager (Amsterdam, Netherlands): Current Status of Radioligand Therapy

16:11 - 16:41 Uwe Haberkorn (Heidelberg, Germany): Identification of New Targets and New Ligands

Educational Objectives

1. Understand the classical steps as well as new approaches for the clinical development of oncological drugs
2. Learn about the current status of radioligand therapy including drugs approved and under clinical development
3. Understand the steps and methods of new targets and new ligands for radioligand therapy

Summary

Radioligand therapy is one of the most exciting and rapidly developing fields in nuclear medicine. The aim of this joint ESMO/EANM session is to teach the audience on what are the required steps of classical and innovative oncological drug development to allow nuclear medicine members to face oncologists at eye level. The five sessions will give an overview of clinical development (phase 0 to 3), introduce new ways of executing early drug development, discuss proposals for Fast-Track Pathways for Approval (FDA, EMA), summarize the current status of radioligand therapy, as well as highlight methods on how to identify new targets and new ligands.

Key Words

Theranostics, Clinical Development, Radioligand Therapy